Interestingly, this analysis identified that HER2-positive patients receiving chemotherapy with tumours expressing high levels of CACNA1H demonstrated a better overall survival after chemotherapy, compared to patients with low levels of CACNA1H in both, METABRIC and KM-Plotter cohorts [Fig. 9a, b (iii, iv)]. This evidence concerns the gene CACNA1H and neoplasm.